Our Science

We are decoding human tissue biology to create a pipeline of next-generation therapeutics for immune-mediated diseases.

At the core of our approach is the realization that correcting disease processes at the tissue level leads to better clinical outcomes. The immune system is critical to the regulation and dysregulation of tissue homeostasis.

Immune cells in the tissues are hard to access, and they operate in highly complex systems. Mouse models are traditionally used to define their behavior, but the differences in tissue immune biology do not always allow for translatable insights needed for successful drug discovery.

Why Tregs?

Regulatory T cells, or Tregs, are a special subset of T cells that act as key regulators of the immune system. In the tissues, Tregs are important players in tissue inflammation and the mediation of tissue healing.

By studying Tregs we can better understand how those regulatory pathways affect other tissue immune and stromal cells.

Tregs modulation is key to therapeutic innovation and TRexBio is at the forefront, building a robust pipeline of transformative medicines addressing cancer, autoimmune diseases and fibrosis.

1000

There are over

tissue T reg enriched genes

95%

of T cells reside and function in tissues

An example of our Treg-enriched scRNA sequencing output across two different skin diseases, highlighting a tissue-Treg enriched pathway in red.

The TRexBio Difference

There is a growing body of scientific research highlighting the unique role of immune cells within the tissue environment. Leveraging a suite of modern computational tools and paired with deep expertise in immunology and drug development, we can decode the regulation of immune-mediated diseases at an unprecedented resolution. We can now access targets in human tissues that were once impossible to reach.

THE TRADITIONAL APPROACH

Murine biology

Validation in peripheral blood

Therapeutic molecule

THE TRex APPROACH

Human tissue biology

Computational biology and functional fingerprinting

Therapeutics built on human tissue-specific hypotheses

The TRexBio Difference

THE TRADITIONAL APPROACH

THE TRex APPROACH

There is a growing body of scientific research highlighting the unique role of immune cells within the tissue environment. Leveraging a suite of modern computational tools and paired with deep expertise in immunology and drug development, we can decode the regulation of immune-mediated diseases at an unprecedented resolution. We can now access targets in human tissues that were once impossible to reach.

The TRexBio Deep Biology Platform

Our Deep Biology Platform allows us to interrogate tissue regulation through the lens of regulatory T cells (Treg). Tregs are key regulators of the immune system. Using recent advances in sequencing technologies and computational methods, we are generating a high resolution ‘map’ of tissue regulatory pathways.

We don’t stop there. Our disease-focused functional genomics platform prioritizes causal pathways in Treg modulation with unprecedented speed and precision. These cutting-edge tools help us elucidate how Tregs regulate tissue inflammation and allow us to identify crucial immune-regulatory pathways for therapeutic innovation.

High Resolution Profiling
Of Human Tissue

Human Tissue
Fresh human tissue in health and disease
RNASeq
Bulk and single cell RNA-seq

Proprietary System To
Recreate Tissue States In Tregs

Cutting-Edge Computational Biology + Disease-Relevant Phenotypic Assays

Treg Atlas
Treg Atlas to generate tissue-like Tregs
Sillicons Hypohtesis
In silico hypotheses integrating human genetics data
Functional Fingerprint
Functional Fingerprint in phenotypic Treg Assay Cascade

Cutting Edge Computational Biology + Disease-Relevant Phenotypic Assays

On Target recreation

Novel targets with strong therapeutic hypothesis

The foundation of our platform is a high-resolution map of tissue immune-regulation in health and disease derived from our broad collection of human tissue. Our Deep Biology Platform produces translatable insights for the initiation of new drug discovery programs.

Our discovery platform is comprised of three pillars:

Modern computational tools

enabling in silico identification of key tissue regulation pathways. This includes high resolution mapping of human tissue, as well as a suite of computational biology tools for identifying pathways.

Our TRex Treg Atlas

recreates human tissue-specific pathways for validation in our TRex Assay Cascade. This includes approximately 1,000 tissue Treg enriched genes, and reprograms blood Treg to capture 70% of those genes.

Our TRex Assay Cascade

a suite of Treg functional assays in a highly optimized workflow. This screens multiple donors and targets concurrently, and it is designed to reveal clinically relevant biology.